Jinwu Financial News | Guichuang Tongqiao (02190) announced that the ZYLOX Penguin static to iliac stent system independently developed by the Group has been approved for listing by the National Drug Administration (NMPA). This marks another landmark advance in the company's overall solution for interventional treatment of peripheral venous disease, and further consolidates its market position and influence in the field of peripheral vascular intervention. As of the date of this announcement, the company has obtained approval from the State Drug Administration for a total of 36 products in China.
The ZYLOX Penguin Iliac Stent System is an innovative medical engineering combination product developed by the Group in cooperation with the First Affiliated Hospital of Chongqing Medical University.